1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-7 of 7 (Search time: 0.005 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Cetuximab for the treatment of colorectal cancerJonker, D.; O'Callaghan, C.; Karapetis, C.; Zalcberg, J.; Tu, D.; Au, H.; Berry, S.; Krahn, M.; Price, T.; Simes, R.; Tebbutt, N.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.
2021Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDSchmoll, H.J.; Stein, A.; van Cutsem, E.; Price, T.; Hofheinz, R.D.; Nordlinger, B.; Daisne, J.F.; Janssens, J.; Brenner, B.; Reinel, H.; Hollerbach, S.; Caca, K.; Fauth, F.; Hannig, C.V.; Zalcberg, J.; Tebbutt, N.; Mauer, M.E.; Marreaud, S.; Lutz, M.P.; Haustermans, K.
2013The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsRosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2008K-ras mutations and benefit from cetuximab in advanced colorectal cancerKarapetis, C.; Khambata-Ford, S.; Jonker, D.; O'Callaghan, C.; Tu, D.; Tebbutt, N.; Simes, R.; Chalchal, H.; Shapiro, J.; Robitaille, S.; Price, T.; Shepherd, L.; Au, H.; Langer, C.; Moore, M.; Zalcberg, J.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.

Discover